<DOC>
	<DOC>NCT00672607</DOC>
	<brief_summary>To compare the efficacy and safety of Agnucaston tablets with placebo for the treatment of Premenstrual Syndrome (PMS) and assess if Agnucaston tablets are superior to placebo on efficacy or not.</brief_summary>
	<brief_title>a Clinical Trial to Evaluate the Efficacy and Safety of Agnucaston Tablets in the Treatment of Premenstrual Syndrome (PMS)</brief_title>
	<detailed_description>Premenstrual syndrome (PMS) is a common disorder in women and consists of somatic and/or behavioral/mood symptoms, which can impair a woman's social and work-related functioning. Some clinical studies with preparations containing Vitex agnus castus have demonstrated a positive effect on PMS with good tolerability. The aim of this clinical trial is to investigate the efficacy and safety of Agnucaston tablets for the therapy of PMS.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Premenstrual Syndrome</mesh_term>
	<criteria>clinical diagnosis of PMS disease Age between 18 and 45 years Patients is in general good health Any of the following endocrinological diseases: diabetes mellitus, hypo/hyperthyreosis, pituitary tumor. Clearly kidney or liver disease, abnormal kidney or liver function. Any of the following gynecological diseases: endometriosis, mammary carcinoma, intraductal papilloma, galactorrhea, mammary fibroadenoma. Prior to the start of the study any planned surgical intervention of the breasts (including cyst puncture), of the uterus and/ or adnexa.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>premenstual syndrome, PMS, clinical trial</keyword>
</DOC>